Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $625

Benzinga · 2d ago
Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $590 to $625.